Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

Sep

Today In Oncology

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Study Finds Postapproval Cancer Trials Fell After Inflation Reduction Act

Incorporating Family Caregivers Into Shared Decision-Making for Patients With Cancer

Clear-Margin Diagnostic Excisional Biopsy May Adequately Treat Melanoma in Situ, Study Finds

Is TBI Associated With Malignant Brain Tumors